News
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive
Results from a large clinical trial in Liberia showed that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses that last for at least one year. One of the two vaccine candidate was co-developed by National Institute of Allergy and Infectious Diseases (NIAID)'s
The National Institutes of Health (NIH) announced $20 million in funding from the Stimulating Peripheral Activity to Relieve Conditions (SPARC) awards program. This program aims to transform our understanding of these nerve-organ interactions and ultimately advance the neuromodulation field toward
The 2017 Deals of Distinction™ Award was presented to National Institutes of Health, (NIH) along with its corporate partners, AbbVie and Biogen, for a license agreement related to the development and launch of Zinbryta® for treatment of relapsing multiple sclerosis (MS) The award, one of the most